New Phase III Data Confirm Phase II Findings of ADVEXIN(R) Efficacy (Centre Daily Times)
Introgen Therapeutics, Inc. (NASDAQ:INGN) today announced that ADVEXIN(R) Phase III clinical trial data in patients with recurrent head and neck cancer confirm earlier Phase II results of ADVEXIN efficacy. Biomarkers of the p53 tumor suppressor gene target of ADVEXIN treatment were predictive in selecting patients more likely to respond to ADVEXIN, a targeted tumor suppressor therapy being ...

FDA Hearings To Examine Regulation Of Embryonic Stem Cell Treatments (Medical News Today)
FDA on Thursday will begin two days of hearings to examine how the agency will regulate human embryonic stem cell therapies, the Wall Street Journal reports. Executives from biotechnology companies, investors, researchers and representatives from patient advocacy groups are expected to attend the hearings, according to FDA officials.